Teva Pharmaceutical Balance Sheet - Annual (NYSE:TEVA)

Add to My Stocks
$24.83 $0.19 (0.77%) TEVA stock closing price Sep 20, 2018 (Closing)

The financial analysis of a company like Teva Pharmaceutical involves checking the three financial statements of the company in detail, of which the balance sheet is one. All three financial statements should be used to measure the financial performance of the company, and should form a part of the Teva Pharmaceutical stock analysis. Annual results announcements include the release of all three financial statements, of which the balance sheet is one. The balance sheet shows total liabilities of $51.87B and shareholders equity of $18.75B. Teva Pharmaceutical revenue and Teva Pharmaceutical operating cash flow are important in understanding the financial capacity of the company.

View latest 10 year balance sheet data to check Teva Pharmaceutical financial performance.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Marketable Securities-------36M253M53M
Raw Materials1.64B1.58B1.38B1.47B1.77B1.88B1.73B---
Work In Progress597M538M535M638M715M751M781M---
Finished Goods2.69B2.83B2.05B2.27B2.57B2.87B2.5B---
Notes Receivable----------
Other Current Assets2.37B3.5B2.14B2.39B2.29B2.4B2.13B1.42B1.54B1.47B
Total Current Assets
Property Plant & Equipment12.18B11.93B10.07B9.88B9.74B9.14B8.38B---
Accumulated Depreciation4.51B3.85B3.53B3.35B3.11B2.82B2.43B---
Net Property Plant & Equipment
Investment & Advances------991M632M534M425M
Other Non-Current Assets----------
Deferred Charges574M725M----142M138M642M-
Deposits & Other Assets932M1.24B2.62B1.57B1.7B1.34B---476M
Total Assets
Notes Payable-------2.77B1.3B2.91B
Accounts Payable2.07B2.16B3.59B3.17B3.32B3.38B3.74B2.53B2.68B2.24B
Current Portion Long-Term Debt3.65B3.28B1.59B1.76B1.8B3.01B4.28B---
Current Portion Capital Leases----------
Accrued Expenses3.56B4.26B--------
Income Taxes Payable----------
Other Current Liabilities8.64B8.82B7.83B7.36B6.84B6.51B5.82B4.4B3.62B3.33B
Total Current Liabilities
Deferred Taxes/Income3.28B5.22B1.75B1.1B1.25B1.85B2.61B1.35B1.74B1.72B
Convertible Debt-------13M817M1.88B
Long-Term Debt28.83B32.52B8.38B8.57B10.39B11.71B10.24B4.1B3.49B3.65B
Non-Current Capital Leases----------
Other Long-Term Liabilities1.84B1.64B1.2B1.11B1.27B1.29B1.11B998M897M803M
Total Liabilities
Minority Interest---------60M
Preferred Stock3.63B3.62B3.29B-------
Common Stock Net54M54M52M50M50M50M50M49M49M48M
Capital Surplus23.48B23.41B17.76B14.12B13.63B13.47B13.37B13.25B12.88B11.5B
Retained Earnings-3.8B13.61B14.85B14.44B12.54B12.35B11.28B9.33B6.66B5.29B
Treasury Stock4.15B4.19B4.23B3.95B3.56B3.09B1.92B1.02B924M924M
Other Liabilities-467M-1.5B-1.8B-1.3B-20M82M-441M405M592M390M
Shareholders Equity18.75B34.99B29.93B23.36B22.64B22.87B22.34B22B19.26B16.3B
Total Liabilities & Shareholders Equity70.62B92.89B54.26B46.42B47.51B50.61B50.14B38.15B33.81B32.9B
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The latest Teva Pharmaceutical stock price, and Teva Pharmaceutical historical stock prices show the stock price movement over time, and the Teva Pharmaceutical PE ratio chart displays the PE ratio movement. Apart from stock price, one should also look at balance sheet items which mainly comprise of the following:

  • Assets: An asset is a resource that a corporation like Teva Pharmaceutical owns and has monetary significance. TEVA assets decreased from $92.89B in 2016 to $70.62B in 2017. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities: This item on the balance sheet implies the firm's, in this case Teva Pharmaceutical's, legal obligations including loans, accounts payable, deferred revenue, accrued expenses and mortgages. The total liabilities for TEVA stock stand at $51.87B.

Teva Pharmaceutical Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio